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East African 
Trypanosomiasis in 
a Pregnant Traveler
To the Editor: Human African 
trypanosomiasis (HAT) results in a 
large number of deaths and consid-
erable illness in sub-Saharan Africa. 
Although the disease is uncommon in 
returning travelers from that region, 
awareness of it is important for medi-
cal practitioners in areas where the 
disease is not endemic. The disease 
can be categorized geographically into 
West and East African trypanosomia-
sis caused by T. brucei gambiense and 
Trypanosoma brucei rhodesiense, re-
spectively, and clinicopathologically 
into hemolymphatic (stage I) disease 
and meningoencephalitic (stage II) 
disease (1). The East African form of 
the disease is less common than the 
West African form and accounts for 
10% of the global incidence of try-
panosomiasis.
Relative stability in East African 
nations may have contributed to the 
lower incidence of the disease in these 
countries, but drought and increasing 
pressure on water sources may lead to 
an upsurge in East African disease. The 
increasing ease of global travel and at-
traction of game safaris and hunting 
may also lead to increasing exposure 
in travelers. HAT is treated with toxic 
drugs in regimens that have changed 
little for decades. Few published data 
exist on the treatment of HAT in preg-
nancy, particularly for East African 
disease. We describe a case of T. bru-
cei rhodesiense infection occurring in 
a pregnant traveler.
A 32-year-old woman, 20 weeks 
pregnant, returned from a 9-day safari 
trip to Tanzania 8 days before coming 
to a hospital in London. She described 
a short history of fever, headache, and 
soft-tissue swelling of the forehead 
with severe regional adenopathy. She 
had evidence of skin necrosis (chan-
cre) (Figure) but no history of tsetse 
ﬂ  y bite. Blood tests showed anemia 
(hemoglobin 9.5 g/dL), leukopenia 
(1.8 × 109 cells/L), and thrombocy-
topenia (60 × 109 cells/L). A blood ﬁ  lm 
showed trypomastigotes of T. brucei 
rhodesiense. Suramin was initially un-
available for treatment, but because of 
her deteriorating clinical state, she was 
treated with 1 dose of pentamidine (4 
mg/kg) before suramin was obtained. 
Suramin was begun 36 hours after 
admission, initially at 5 mg/kg and in-
creased over the next 2 doses up to 1 g. 
During the next 48 hours, her fever re-
solved, and serial blood ﬁ  lms showed 
clearance of the parasites from the 
blood. A cerebrospinal ﬂ  uid  sample 
showed no signs of stage II disease, 
and the patient continued on suramin, 
completing a standard course as an 
outpatient. Her pregnancy was closely 
monitored, and she gave birth at term 
to a healthy baby girl.
The treatment of choice for stage 
I HAT caused by T. brucei gambiense 
is parenteral pentamidine (1). No 
published trials compare pentamidine 
and suramin in East African trypano-
somiasis, but longstanding consensus 
suggests that suramin is more likely to 
be efﬁ  cacious in stage I East African 
disease (1). The basis for this differ-
ence in efﬁ  cacy is unexplained.
Theoretically, pentamidine may 
be teratogenic because it inhibits pro-
tein and nucleic acid synthesis in vitro 
(2). However, studies in rats found 
pentamidine to be feticidal but not 
teratogenic (3). Pentamidine has been 
used extensively for HAT prophylaxis 
without reported problems (4) and has 
had limited use in pregnant women 
with Pneumocystis jirovecii pneumo-
nia. It continues to be recommended 
in pregnant women with stage I HAT 
originating in West Africa. Suramin is 
known to cause a syndrome similar to 
preeclampsia in pregnant rats (5), yet it 
too has been used in large-scale treat-
ment programs for onchocerciasis, and 
no fetal or placental effects have been 
reported in humans (2,6). We found 1 
case report describing successful use 
of suramin, followed by melarsoprol, 
in a pregnant woman with HAT (7).
The treatment of stage II disease 
in pregnancy is problematic, and pub-
lished information to guide therapy 
is lacking. Although the effect of ar-
senicals on fetuses is a concern, case 
reports have described the successful 
use of melarsoprol during pregnancy 
(7,8); if left untreated, the disease is 
fatal. Thus, if our patient had stage II 
disease, use of melarsoprol, which is 
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Figure. Chancre at site of tsetse ﬂ  y bite on forehead of pregnant patient with trypanosomiasis. 
A color version of this ﬁ  gure is available online (www.cdc.gov/EID/content/15/11/1866-F.
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often given with prednisolone, would 
have been necessary.
In pregnant women with West 
African (T. brucei gambiense) stage 
II disease, either melarsoprol or ef-
lornithine can be used, but neither 
is effective for East African disease. 
Although eﬂ  ornithine can abort early 
pregnancies and cause disordered or-
ganogenesis (9), the severe enceph-
alopathy associated with melarsoprol 
makes eﬂ  ornithine a preferable option 
for single-agent treatment. However, 
nifurtimox–eﬂ  ornithine  combination 
therapy will soon replace single-drug 
regimens for stage II T. brucei gambi-
ense cases (10).
We believed evidence was insuf-
ﬁ  cient to withhold suramin therapy for 
this highly fatal disease. Because of 
the uncertainty about effects of preg-
nancy on the ability to clear trypano-
somes, the patient will be followed 
up for signs of relapse. The danger of 
HAT should be speciﬁ  cally highlight-
ed for all travelers to trypanasomiasis-
endemic regions, particularly pregnant 
travelers because of potential harm to 
unborn children.
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Rickettsia africae 
Infection in Man 
after Travel to 
Ethiopia
To the Editor: The ﬁ  rst human 
case of African tick-bite fever was de-
scribed in 1992 as occurring in Zimba-
bwe. The causative agent was identi-
ﬁ  ed as a new serotype of the spotted 
fever group (SFG) rickettsiae and 
named  Rickettsia africae ( 1). These 
ﬁ  ndings conﬁ  rmed observations made 
by Pijper in the 1930s which suggest-
ed that there were 2 different kinds of 
human SFG rickettsioses in sub-Sa-
haran Africa: Mediterranean spotted 
fever caused by R. conorii and trans-
mitted by Rhipicephalus species, ticks 
of dogs, and African tick-bite fever 
caused by R. africae and transmitted 
by Amblyomma species, ticks of cattle 
and wild ungulates. African tick-bite 
fever has subsequently been diag-
nosed in patients from several other 
sub-Saharan countries and also from 
the West Indies (2,3).
In a recent analysis of the spec-
trum of diseases among returning trav-
elers, tick-borne spotted fever was (af-
ter malaria) the second most frequent 
cause of systemic febrile illness among 
those returning from sub-Saharan Af-
rica. It occurred more frequently than 
typhoid fever and dengue fever (4). 
The following case description reports 
an infection with R. africae in a man 
in France who recently returned from 
Ethiopia. 
On November 4, 2005, a 62-year-
old French man sought care at the 
Medical Center of the Institut Pasteur 
in Paris for fever, along with chills, 
headache, neck and shoulder pain, 
and fatigue over the previous 4 days. 
At the onset of these symptoms he 
had noticed dark nodular lesions on 
his neck and his left groin followed 2 
days later by a slightly painful erup-
tion on his arms and his trunk. He had 
spent a month in southwest Ethiopia, 
north of Kelem near the Sudanese bor-
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